logo
Nestle recalling select Lean Cuisine, Stouffer's meals due to possible ‘wood-like material'

Nestle recalling select Lean Cuisine, Stouffer's meals due to possible ‘wood-like material'

Yahoo18-03-2025

(KNWA/KFTA) — Nestle says it has issued a recall for a limited quantity of Lean Cuisine and Stouffers meals due to the possibility they contain 'wood-like material', according to a news release.
The recall is for batches of Lean Cuisine Butternut Squash Ravioli, Lean Cuisine Spinach Artichoke Ravioli, Lean Cuisine Lemon Garlic Shrimp Stir Fry, and Stouffer's Party Size Chicken Lasagna that were produced between August 2024 and March 2025.
The products were distributed at major retailers throughout the U.S. between September 2024 and March 2025.
More cat food recalled due to 'bird flu' risk
Nestle said it issued the recall after consumers contacted them about the issue, including one choking report.
These batches are impacted by the recall:
Lean Cuisine Butternut Squash Ravioli
Batch Number 4261595912; Best-By Date: October 2025
Batch Number: 4283595912; Best-By Date: November 2025
Batch Number: 4356595912; Best-By Date: January 2026
Batch Number: 5018595912; Best-By Date: February 2026
Batch Number: 5038595912; Best-By Date: March 2026
Lean Cuisine Spinach Artichoke Ravioli
Batch Number: 4261595912; Best-By Date: October 2025
Batch Number: 4283595912; Best-By Date: November 2025
Batch Number: 4356595912; Best-By Date: January 2026
Batch Number: 5018595912; Best-By Date: February 2026
Batch Number: 5038595912; Best-By Date: March 2026
Lean Cuisine Lemon Garlic Shrimp Stir Fry
Batch Number: 4214595511; Best-By Date: September 2025
Stouffers Party Size Chicken Lasagna (96-ounce)
Batch Number: 4262595915; Best-By Date: October 2025
Batch Number: 4351595915; Best-By Date: January 2026
Batch Number: 5051595915; Best-By Date: March 2026
Batch Number: 5052595915; Best-By Date: March 2026
Nestle said no other meals have been impacted by the recall as of March 18.
Ohio company recalls 15,000 cases of oyster crackers
'We are actively investigating the source of the wood-like material, Nestle said in the release. 'We are confident that this is an isolated issue, and we have taken action to address it.'
Anyone who has purchased any of the affected products is asked to return it to where it was purchased for a replacement or full refund.
Nestle said anyone with questions about the recall can call 800-681-1676 Monday through Friday from 9 a.m. to 6 p.m. EST.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor
Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor

Yahoo

timean hour ago

  • Yahoo

Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor

PEACHTREE CORNERS, Ga., June 10, 2025--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that it had received a purchase order and first payment from Hangzhou Dongye Medical Technology Company Ltd (HDMT) for 35 LuViva systems. HDMT will order directly from Guided Therapeutics and the devices will be assembled and tested by Guided Therapeutics' Chinese partner, Shandong Yaohua Medical Instrument Corporation (SMI). HDMT is in Hangzhou City, Zhejiang Province, where it is the exclusive gynecology products provider for 42 hospitals that perform approximately two million cervical cancer screenings annually. Said Yang Dongye, CEO of HDMT: "We are extremely impressed with the performance of LuViva and our goal is to eventually replace the current screening tests with LuViva." The purchase order for $700,000 is to supply HDMT with 35 systems over the next eight months starting in July of this year. "We are extremely pleased to be working with HDMT to bring LuViva to Zhejiang Province and anticipate making initial shipments next month," added Mark Faupel, Guided Therapeutics' CEO. "Working directly with an exclusive provider of gynecology products that can potentially conduct two million LuViva tests each year is a major advance for GTI." About Guided Therapeutics Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company's first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc. Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics' actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of commercialization of products, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in prior financings and the ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading "Risk Factors" in Guided Therapeutics' reports filed with the SEC, including Guided Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and subsequent filings. View source version on Contacts Mark FaupelGuided Therapeutics770-242-8723

GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients
GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients

Yahoo

timean hour ago

  • Yahoo

GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients

ATLANTA, GA - June 10, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies against infectious diseases and solid tumors, today announced that clinical data for its next-generation COVID-19 multi-antigen vaccine candidate, GEO-CM04S1, will be presented at the European Hematology Association (EHA) 2025 Hybrid Congress, taking place June 1215, 2025, in Milan, Italy and online. Alexey V. Danilov, M.D., Ph.D., Associate Director of the Toni Stephenson Lymphoma Center and Professor in the Department of Hematology and Hematopoietic Cell Transplantation at the City of Hope Comprehensive Cancer Center in Duarte, California, will present a poster titled: "MVA-Based GEO-CM04S1 Vaccine Results in Improved Cellular Immune Response in Patients with Chronic Lymphocytic Leukemia (CLL) Compared with mRNA-Based Vaccine: Initial Results of a Phase II Randomized Study". The poster will be featured on Saturday, June 14, 2025, from 18:30 to 18:30 CEST in the Poster Hall, as part of the session on Infections in Hematology (including supportive care/therapy). The presentation will highlight initial results from a Phase II randomized clinical trial highlighting the superior cellular immune response of GEO-CM04S1 compared to an authorized mRNA-based COVID-19 vaccine in CLL patients - a population known to exhibit suboptimal protective responses to COVID-19 and other vaccines due to immune dysfunction. The findings will underscore the differentiated mechanism and clinical potential of the GeoVax MVA multi-antigen platform, particularly in immunocompromised individuals. "GEO-CM04S1 continues to show promise as a vaccine option for populations with suboptimal protection from existing COVID-19 vaccines," said Kelly T. McKee, Jr., M.D., Chief Medical Officer of GeoVax. "We are proud to have these important data showcased at EHA2025, reflecting the real-world needs of patients with hematologic malignancies." About GEO-CM04S1 GEO-CM04S1 is a multi-antigen COVID-19 vaccine designed using a synthetic Modified Vaccinia Ankara (MVA) vector platform. The vaccine expresses both spike (S) and nucleocapsid (N) antigens of SARS-CoV-2, aiming to provide broader and more durable immune protection. It is currently being evaluated in Phase 2 clinical trials in both immunocompromised and healthy adults. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: Company Contact:info@ Investor Relations Contact:geovax@ Sign in to access your portfolio

Nika Pharmaceuticals, Inc. to Present at the Life Sciences Virtual Investor Forum June 11th-12th
Nika Pharmaceuticals, Inc. to Present at the Life Sciences Virtual Investor Forum June 11th-12th

Yahoo

time2 hours ago

  • Yahoo

Nika Pharmaceuticals, Inc. to Present at the Life Sciences Virtual Investor Forum June 11th-12th

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at HENDERSON, Nev., June 10, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB:NIKA), based in Colorado, focused on cures for life-threatening diseases, today announced that Dimitar Savov, CEO, will present live at the Life Sciences Virtual Investor Frum hosted by on June 11th, 2025 DATE: June 11th TIME: 1:00 PM ETLINK: REGISTER HEREAvailable for 1x1 meetings: June 12th-17th between 09:00am ET and 11:30am ET This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at Recent Company Highlights On May 19, 2025, NIKA published a market analysis for the countries of Ukraine, Syria, Jordan, Iraq, UAE, where NIKA has exclusive distribution agreements and has estimated a total of around €656 million in potential revenue. NIKA's partner company, Nika Europe, has made the second $195,554 payment for the vial production line and is currently finalizing the details of the clean rooms design in order to start construction. The production facility is expected to be completed in H2, 2025. On April 11, 2025, Nika Pharmaceuticals, Inc. published a report on the therapeutic effect and potential economic impact of ITV-1, which can be found here. On July 11, 2024 Nika Pharmaceuticals, Inc. signed an exclusive distribution agreement for the Republic of Nigeria. Under the terms, NIKA will receive €1,980 per each set of ITV-1 with two sets necessary for each treatment, which could result in €7.9 billion revenue. About Nika Pharmaceuticals, Inc. Nika Pharmaceuticals, Inc. (NIKA) is a pharmaceutical company, specializing in the treatment of HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, Diabetes, and all diseases, for which strengthened cell immunity is of vital importance. NIKA's intellectual property includes six drugs in injection form – two of which have successfully undergone clinical trials with good treatment results – four drugs in tablet form, and eleven dietary supplements. NIKA's goal is to not only achieve corporate profits, but to provide better and easier access to life-saving medicinal drugs and useful dietary supplements. Find more on Forward-looking Statement: This press release contains forward-looking statements. Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are 'forward- looking statements.' These forward-looking statements generally are identified by the words 'believes,' 'expects,' 'anticipates,'' estimates,' 'intends,' 'strategy,' 'plan,' 'may,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result,' and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. About Virtual Investor Conferences®Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. CONTACTS:Nika Pharmaceuticals, Clifford P. RedekopTitle Corporate SecretaryPhone (702) 326-3615 Email cliffredekop@ Virtual Investor Conferences John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group (212) 220-2221johnv@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store